Evidence map›Paper›PMID 39564511›Full record

ArticleFrontiers in medicine2024

Measles surveillance data analysis and serological survey in Quzhou, China, 2014-2024: an assessment of progress toward measles elimination.

Xiaoying Gong, Wangfeng Zheng, Shiming Lai, Zhiying Yin

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoying Gong *Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Wangfeng Zheng *Department of Orthopedics, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, Zhejiang, China.
Shiming Lai *Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.
Zhiying YinDepartment of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Measles is a disease that can be eliminated through vaccination. In recent years, measles incidence and mortality have been greatly reduced. Methods: Analyze measles surveillance data from 2014 to 2023 and measles seroepidemiological characteristics of healthy populations in 2024 to assess progress toward measles elimination. Results: A total of 35 measles cases were reported in the surveillance system from 2014-2023 in Quzhou, with an average annual incidence of 1.6/1 million. Since 2019, the incidence of measles has been lower than 0.5/1 million. A serological survey of 257 healthy people showed that the positive rate of measles IgG antibody was 90.3%, and the immunity of all age groups except 0-5 years old was lower than 95%, which did not reach the threshold of 95% herd immunity required for eliminating measles. Conclusion: Although the incidence of measles in Quzhou is low, the immunity of healthy people to measles infection is insufficient. Measles is still in the control phase, not in the elimination phase. Inadequate immunity in the population may be due to the failure to achieve ≥95% vaccination coverage and low immunogenicity of the vaccine. Recommends that the quality of routine immunization data be assessed and monitored to verify reported vaccination coverage; at the same time, improve vaccination services and optimize vaccination policies to increase actual vaccination coverage. In addition, it is recommended to adjust the MMR immunization strategy, changing the time of the first MMR vaccination from 8 months of age to 12-15 months of age, and the second dose at 4 to 6 years of age.

Indexed as

antibodyeliminationincidencemeaslessurveillancevaccination

Identifiers

PMID39564511
PMCPMC11573565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.